摘要
目的：探讨加味八珍汤联合放化疗对中晚期宫颈癌疗效及对患者T细胞亚群水平、血清肿瘤标志物表达及生存期的影响。方法：2009年2月—2012年5月河南省中医院共收治177例中晚期宫颈癌患者,以该批患者为研究对象,随机数字表法分为治疗组（89例）,对照组（88例）。对照组采用同步放化疗法治疗,治疗组患者在此基础上加用加味八珍汤进行治疗,比较两组患者治疗后的近期疗效,T细胞亚群水平,血清肿瘤标志物表达及生存期。结果：治疗组患者总有效率为87.64%,对照组为73.86%,治疗组优于对照组（P〈0.05）;经治疗,两组CD3^＋,CD4^＋水平,CD4^＋/CD8^＋均有明显上升,CD8^＋水平明显下降（P〈0.05）;与对照组相比,治疗组CD3^＋,CD4^＋水平与CD4^＋/CD8^＋明显升高,CD8^＋水平明显降低（P〈0.05）;经治疗,两组患者血清中糖链抗原125（carbohydrate antigen125,CA125）,鳞状上皮癌相关抗原（squamous cell carcinoma associated antigen,SCCA）以及癌胚抗原（carcino-embryonic antigen,CEA）表达均明显降低（P〈0.05）,与对照组治疗后相比,治疗组上述指标明显降低（P〈0.05）;治疗组患者1,2,3,5年生存率分别为91.01%,55.06%,26.97%,13.48%,相比于对照组的73.86%,32.95%,9.09%,3.41%,治疗组患者生存期明显长于对照组（P〈0.05）。结论：加味八珍汤联合放化疗可以明显提高中晚期宫颈癌患者的机体免疫力,降低血清肿瘤标记物的水平,延长中晚期患者的生存时间,对中晚期宫颈癌具有积极的治疗效果。
Objective： To study the clinical efficacy of modified Bazhentang combined with radiotherapy and chemotherapy in treating middle and advanced cervical cancer and investigate its effect on T cell subset,serum tumor markers and survival period.Method： The 177 patients with middle and advanced cervical cancer in our hospital from February 2009 to May 2012,were selected and divided into treatment group（89 cases） and control group（88 cases） according to the random number table.Patients in two groups were treated with radiotherapy and chemotherapy,while the patients in treatment received additional modified Bazhentang.Then the short-term efficacy,T cell subset,serum tumor markers and survival period of the two groups were compared.Result： The total effective rate was 87.64% in treatment group,better than 73.86% in control group（P〈0.05）.After the treatment,the levels of CD3^＋,CD4^＋ and CD4^＋ /CD8^＋ were significantly increased in both groups,but the level of CD8^＋ was significantly decreased（P〈0.05）.After the treatment,the levels of CD3^＋,CD4^＋ and CD4^＋ /CD8^＋ in treatment group were significantly higher than those in control group,while the level of CD8^＋ was significantly lower than that of control group（P〈0.05）.The expression levels of carbohydrate antigen 125（CA125）,squamous cell carcinoma associated antigen（SCCA） and carcino-embryonic antigen（CEA） were significantly decreased in both groups after treatment,and the decrease was more obvious in treatment group（P〈0.05）.The 1,2,3,5-year survival rate was 91.01%,55.06%,26.97%,13.48% respectively in treatment group,higher than 73.86%,32.95%,9.09%,3.41% in control group（P〈0.05）.Conclusion： Modified Bazhentang can significantly improve the immunity,reduce the level of serum tumor markers and prolong the survival time of the patients,so it has positive therapeutic effect on middle and advanced cervical cancer.
出处
《中国实验方剂学杂志》
CAS
CSCD
北大核心
2018年第4期174-179,共6页
Chinese Journal of Experimental Traditional Medical Formulae
基金
河南省科技厅科技攻关项目(162102310186)
关键词
加味八珍汤
中晚期宫颈癌
疗效
T细胞亚群
血清肿瘤标志物
生存期
modified Bazhentang
middle and advanced cervical cancer
clinical efficacy
T cell subset
serum tumor markers
survival period
作者简介
宋晓婕，硕士，主治医师，从事妇科肿瘤研究，Tel：0371—86056877，E-mail：jiewenxiu11@sina.com;[通信作者]周艳艳，博士，副主任医师，副教授，从事妇产科临床工作，Tel：0371—86056877，E-mail：zhouyanyan_17@sina.com
